Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2006 4
2007 2
2008 5
2009 18
2010 49
2011 47
2012 78
2013 80
2014 79
2015 94
2016 73
2017 93
2018 94
2019 88
2020 116
2021 117
2022 107
2023 132
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

1,118 results

Results by year

Filters applied: . Clear all
Page 1
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis in a 1:1 ratio …
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated …
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suárez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear CA, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW; PEXIVAS Investigators. Walsh M, et al. N Engl J Med. 2020 Feb 13;382(7):622-631. doi: 10.1056/NEJMoa1803537. N Engl J Med. 2020. PMID: 32053298 Free PMC article. Clinical Trial.
Patients were randomly assigned to undergo plasma exchange (seven plasma exchanges within 14 days after randomization) or no plasma exchange (control group). Patients were also randomly assigned to follow either a standard-dose regimen or a reduced-dose regim …
Patients were randomly assigned to undergo plasma exchange (seven plasma exchanges within 14 days after randomization) or no p …
ANCA-Associated Vasculitis: Core Curriculum 2020.
Geetha D, Jefferson JA. Geetha D, et al. Am J Kidney Dis. 2020 Jan;75(1):124-137. doi: 10.1053/j.ajkd.2019.04.031. Epub 2019 Jul 26. Am J Kidney Dis. 2020. PMID: 31358311 Review.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction of small- and medium-sized blood vessels and the presence of circulating ANCA. Clinical disease phenotypes include granulomatosis wi …
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of disorders characterized by inflammation and destruction …
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Ferraro A, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani R, McAlear C, Moreland LW, Mynard K, Nachman P, Pagnoux C, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Wroe C, Jayne D, Merkel PA; RITAZAREM co-investigators. Smith RM, et al. Ann Rheum Dis. 2023 Jul;82(7):937-944. doi: 10.1136/ard-2022-223559. Epub 2023 Mar 23. Ann Rheum Dis. 2023. PMID: 36958796 Free PMC article. Clinical Trial.
OBJECTIVE: Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. ...METHODS: RITAZAREM was an internatio …
OBJECTIVE: Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated …
ANCA associated vasculitis.
Hunter RW, Welsh N, Farrah TE, Gallacher PJ, Dhaun N. Hunter RW, et al. BMJ. 2020 Apr 14;369:m1070. doi: 10.1136/bmj.m1070. BMJ. 2020. PMID: 32291255 Free PMC article. No abstract available.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA. Chung SA, et al. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-1105. doi: 10.1002/acr.24634. Epub 2021 Jul 8. Arthritis Care Res (Hoboken). 2021. PMID: 34235880
OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with p …
OBJECTIVE: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associate …
Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H; LoVAS Collaborators. Furuta S, et al. JAMA. 2021 Jun 1;325(21):2178-2187. doi: 10.1001/jama.2021.6615. JAMA. 2021. PMID: 34061144 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This was a phase 4, multicenter, open-label, randomized, noninferiority trial. A total of 140 patients with newly diagnosed ANCA-associated vasculitis without severe glomerulonephritis or alveolar hemorrhage were enrolled between N …
DESIGN, SETTING, AND PARTICIPANTS: This was a phase 4, multicenter, open-label, randomized, noninferiority trial. A total of 1 …
Risk factors for serious infections in ANCA-associated vasculitis.
Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, St Clair W, Fervenza F, Geetha D, Monach P, Jayne D, Smith RM, Rosenkranz A, Specks U, Stone JH, Kronbichler A; RAVE−ITN Research Group. Odler B, et al. Ann Rheum Dis. 2023 May;82(5):681-687. doi: 10.1136/ard-2022-223401. Epub 2023 Jan 26. Ann Rheum Dis. 2023. PMID: 36702528 Free PMC article.
This study aimed to identify risk factors associated with severe infections in participants of the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial. METHODS: Data on 197 patients recruited into the RAVE trial were analysed. ...RESULTS: E …
This study aimed to identify risk factors associated with severe infections in participants of the Rituximab versus Cyclophosphamide for ANC …
Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis.
Benichou N, Charles P, Terrier B, Jones RB, Hiemstra T, Mouthon L, Bajema I, Berden A, Thervet E, Guillevin L, Jayne D, Karras A; French Vasculitis Study Group (FVSG) and European Vasculitis Society (EUVAS) investigators. Benichou N, et al. Kidney Int. 2023 Jun;103(6):1144-1155. doi: 10.1016/j.kint.2023.02.029. Epub 2023 Mar 20. Kidney Int. 2023. PMID: 36940799 Clinical Trial.
To study this, our post hoc analysis included participants of five European randomized clinical trials on AAV (MAINRITSAN, MAINRITSAN2, RITUXVAS, MYCYC, IMPROVE). ...
To study this, our post hoc analysis included participants of five European randomized clinical trials on AAV (MAINRITSAN, MAI …
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.
Sánchez Álamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T, Hruskova Z, Jayne D, Luqmani R, Mahr A, Åkesson A, Westman K; EUVAS. Sánchez Álamo B, et al. Nephrol Dial Transplant. 2023 Jun 30;38(7):1655-1665. doi: 10.1093/ndt/gfac320. Nephrol Dial Transplant. 2023. PMID: 36617233
Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective randomized controlled trials (RCTs). The aim for the present study was to further evaluate the long-term survival of patients with AAV …
Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective …
1,118 results